Main Article Content


Background: Rheumatoid arthritis (RA) is a disease involving various types of cytokines. One of them is interleukin-17 (IL-17), which is known to have a pleiotropic effect on various of cells and is thought to be a cytokine effector contributing to the pathogenic
condition in RA.

Methods: The study was conducted on 46 RA patients at rheumatology clinic at the Cipto Mangunkusumo General Hospital who were diagnosed based on the 1987 American College of Rheumatology criteria. Sample selection was done using consecutive sampling. Tests on patients were conducted to collect data needed to obtain the scores for 28-joint Disease Activity Score (DAS28), global health visual analogue scale, swollen joint count, tender joint count, sedimentation rate, Sharp score (radiograph of both hands), and the IL-17 level.
The correlation between IL-17 level and DAS28 was  calculated using the Pearson’s correlation test while the correlation between IL-17 level and Sharp score was calculated using the Spearman’s test.

Results: The majority of patients (87%) were women. The largest percentage was in the 51- to 60-year-old group (39.1%). Most patients (43.1%) had moderate disease activity. There were 27 patients (58.69%) with positive rheumatoid factor. The mean IL-17 level was
17.28 pg/mL with a standard deviation of 11.43 pg/mL. There was no correlation of IL-17 level with disease activity (p = 0.446, r = 0.021) and Sharp score (p = 0.304, r = 0.077) in subjects of this study.

Conclusion: There was no signifi cant correlation of IL-17 with disease activity and joint damage.

Article Details

How to Cite
Ongkowijaya, J. A., Setiyohadi, B., Manuaba, I. A. R. W., & Kasjmir, Y. I. (2018). Correlation of interleukin-17 with disease activity and hand joint damage in patients with rheumatoid arthritis. Indonesian Journal of Rheumatology, 2(2).


  1. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Eng J Med 2009;361:888–98.
  2. Anderson AK, Li C, Brennan FM. Recent developments in the immunobiology of rheumatoid arthritis. Arthritis Res Ther 2008;10:204–12
  3. Firestein GS. Etiology and pathogenesis of rheumatoid arthitis. Dalam: Firestein GS, Budd RC, Harris Jr ED, McInnes IB, Ruddy S, Sergent JS, editors. Kelley’s Textbook of rheumatology. 8th ed. Philadelphia:Saunders; 2009. p. 1035–86.
  4. Fox DA. Etiology and pathogenesis of rheumatoid arthritis. In: Koopman WJ, Moreland LW, editors. Arthritis and allied conditions: a textbook of rheumatology, 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.p. 1089–117.
  5. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008;118:3537–45.
  6. Haugeberg G, Ørstavik RE, Kvien TK. Effect of rheumatoid arthritis
  7. on bone. Curr Opin Rheumatol [serial online] 2003 [cited 2010 March];15(4):[9 screens]. Available from: URL:http://www.medscape.
  8. com/viewarticle/457990.
  9. Agarwal V, Malaviya AN. Cytokine network and its manipulation in rheumatoid arthritis. J Indian Rheumatol Assoc 2005;13:86–91.
  10. DAS-Score [Online]. [cited 2010 March]; Available from: URL:
  11. Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al. DAS28 using c-reactive protein underestimate disease activity and overestimates EULAR response criteria compared using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 2007;66:1356–62.
  12. Sharp JT. Radiologic assessment as an outcome measure in rheumatoid arthritis. Arthritis Rheum 1989;32(2):221–9.
  13. Sokka T. Radiographic scoring in rheumatoid arthritis: a short introduction to the methods. Bull NYU Hosp Jt Dis 2008;66(2):166–8.
  14. Silman AJ, Hochberg MC. Descriptive epidemiology of rheumatoid arthritis. Dalam: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatoid arthritis. Philadelphia: Mosby; 2009.p. 15–22.
  15. Ciprandi G, Fenogllio D, De Amici M, Quaglini S, Negrini S, Filaci G. SerumIL-17 levels in patients with allergic rhinitis. J Allergy Clin Immunol 2008;122(3):650–1.
  16. Arican O, Arl M, Sasmz S, Ciragli P. Serum levels of TNF-ï¡, IFN-ï§, IL-6, IL- 12, IL-17 and IL-18 in patients with active psoriasis and correlation with disease severity. Med of Infl ammation 2005;5:273–9.
  17. Hussein MR, Fathi NA, El-Din AME, Hassan HI, Abdullah F, Al-Hakeem E, et al. Alteration of the CD4+, CD8+ T cell subsets, interleukins-1β, IL-10, IL-17, tumor necrosis factor-α and soluble intercellular adhesion molecule-1 in rheumatoid arthritis and osteoarthritis: preliminary observations. Pathol Oncol Res 2008;14:321–8.
  18. Shahrara S, Huang QQ, Mandelin II AM, Pope RM. Th-17 cells in rheumatoid arthritis. Arthritis Res Ther 2008;10:R93–9.
  19. Romagnani S. Human Th17 Cells. Arthritis Res Ther 2008;10:206–13. 18. Yamada H, Nakashima Y, Okazaki K, Mawatari T, Fukushi JI, Kaibara N, et al. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:1299–304.
  20. Zrioual S, Toh ML, Tournadre A, Zhou Y, Cazalis MA, Pachot A, et al. Il-17RA and IL-17RC are essential for IL-17A-induced ELR CXC chemokineexpression in synoviocytes and are overexpressed in rheumatoid blood. J Immunol 2008;180:655–63.
  21. Abbas AK, Lichtman AH, Pillai S. Cytokine. Dalam: Cellular and molecular immunology. 6th ed. Philadelphia: Saunders; 2007. p. 267–70.
  22. Paradowska A, Maslinkis W, Grzybowska-Kowalczyk A, Lacki J. The function of interleukin-17 in the pathogenesis of rheumatoid arthritis.Arch Immunol Ther Exp 2007; 55:329–34.
  23. Gaffen SL. The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Curr Rheumatol Rep 2009;11(5):365–70.
  24. Moran EM, Mullan R, McCormick J, Connolly M, Sullivan O, Fitzgerald O, et al. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumor necrosis factoralpha, oncostatin M and response to biologic therapies. Arthritis Res Ther 2009;11:R113–24.

Most read articles by the same author(s)